NanoViricides, Inc. Demands Retraction of the Baseless & Inaccurate Libelous Article by an Anonymous Short Seller Posted on S...
February 14 2014 - 7:00AM
Business Wire
NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”) has demanded
from Seeking Alpha the removal of a damaging, baseless and
inaccurate article posted by a person who was shorting NNVC common
stock.
It is obvious that the anonymous author of this article
orchestrated the publication of this article in connection with a
massive short position which this person was a major beneficiary
of, possibly in collusion with others. The article was clearly
designed to manipulate the price of the Company’s common stock
downwards for significant personal gains for the persons with short
position in the stock including this anonymous author, at the
expense of the Company’s shareholders. The article is pure libel,
full of numerous false statements, inaccuracies, innuendos, is not
based on any factual information about the Company, and twists many
facts to fit the person’s motivation to cause a damaging view about
the Company. The article has caused significant damage to the
Company and its shareholders.
The Company has demanded retraction of the article from the
SeekingAlpha website and disclosure of the identity of the
anonymous person who posted it. The full text of the demand is
posted on our website under the item: “NanoViricides Demands
Retraction of the Damaging Article by an Anonymous Short Seller
Posted on SeekingAlpha Website”.
The Company is also preparing a complaint to file with the
Securities and Exchange Commission to request it to investigate
this stock price manipulation.
NanoViricides, Inc. is fully prepared to seek appropriate legal
action against parties involved in this libelous attack.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating
special purpose nanomaterials for viral therapy. The Company's
novel nanoviricide® class of drug candidates are designed to
specifically attack enveloped virus particles and to dismantle
them. The Company is developing drugs against a number of viral
diseases including H1N1 swine flu, H5N1 bird flu, seasonal
Influenza, HIV, oral and genital Herpes, viral diseases of the eye
including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue
fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities. Although
it is not possible to predict or identify all such factors, they
may include the following: demonstration and proof of principle in
pre-clinical trials that a nanoviricide is safe and effective;
successful development of our product candidates; our ability to
seek and obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our
product candidates; and market acceptance of our products.
NanoViricides, Inc.Amanda Schuon, 310-550-7200info@nanoviricides.com
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Sep 2024 to Oct 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Oct 2023 to Oct 2024